MSH2 and Lynch syndrome: Mutations in DNA mismatch repair genes associated with Lynch syndrome (MLH1, MSH2, PMS2, MSH6, and EPCAM) have been associated with a modest increase in prostate cancer risk, particularly for MSH2 [2,3].